Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
External link for Gain Therapeutics
4800 Montgomery Ln
Suite 220
Bethesda, Maryland 20814, US
Via Francesco Soave 6
Lugano, Ticino 6900, CH
Parc Cientific de Barcelona Carrer Baldiri Reixac 4-10
Barcelona, ES
Gain Therapeutics reposted this
Gene Mack, interim CEO of Gain Therapeutics, discusses the company’s platform technology, how its experimental therapy for Parkinson’s disease works, and what other conditions might be good candidates for its platform technology to target. https://lnkd.in/gASMQvk7
Gain Therapeutics Initiates Phase 1b Clinical Trial Of Lead Candidate GT-02287 In People With GBA1 and Idiopathic Parkinson's Disease "...Gain Therapeutics welcomes the New Year and we are excited to take another critical step towards advancing GT-02287 into Phase 2 trial preparation in 2025 following results of the Phase 1b trial, expected mid-year 2025,” said Gene Mack, CFO and Interim CEO of Gain Therapeutics. Read the full press release here: https://lnkd.in/gnWKk6j5
Gain Therapeutics reposted this
Understanding the biology of Parkinson’s disease and turning that knowledge into better treatments is a complex undertaking. In the newest episode of our award-winning Parkinson’s Science POV series, scientists at MJFF discuss how they are tackling this problem from every angle. In the episode, we sit down with MJFF Chief Program Officer Sohini Chowdhury and other staff members to discuss their work, the projects they’re most proud of and their hopes for 2025. Whether it’s using cutting-edge imaging to get a picture of the disease in the brain or working with the community to develop better options to treat walking difficulties, our researchers are collaborating to discover the next wave of treatment options and close in on a cure. Listen to the episode: https://bit.ly/4g3nPSp
Catch us in San Francisco! Read the full press release here: https://lnkd.in/g86Y3p-g
Gain Therapeutics reposted this
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287 is being evaluated in the clinic for the treatment of Parkinson’s disease and other neurodegenerative diseases. Meet Gain Therapeutics, Inc. @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry
We are looking forward to it!
🎤 Gain Therapeutics, Inc. Presenting at Biotech Showcase™! Gene Mack, Chief Financial Officer and Interim CEO of Gain Therapeutics (NASDAQ: GANX), will present on the company’s approach of combining physics-based methods with artificial intelligence to develop best-in-class small molecules for disorders with high unmet medical needs. As a publicly traded company based in Bethesda, Maryland, Gain Therapeutics focus areas include #CNS disorders and #neurological conditions. 🗓️ Register to attend and learn more: https://lnkd.in/eA6it3ct Biotech Showcase, alongside Seed Showcase and TechBio Showcase, provides private and micro- to mid-cap biotechnology companies with a premier platform to present their innovations directly to investors and biopharmaceutical executives. Join us in San Francisco, January 13–15, 2025, with virtual sessions on January 16–17 on the partneringONE platform, to showcase your organization and connect with strategic partners. 📝 Apply to present your innovations: https://lnkd.in/eZP2FXnE 🌁 What to expect at Biotech Showcase: https://lnkd.in/eminMpjK #BiotechShowcase #DemyColton #EBDGroup #Biotech #ArtificialIntelligence #DrugDiscovery #CNS #Neurology #Innovation #Investors #Partnering #GainTherapeutics EBD Group Demy-Colton
Gain Therapeutics reposted this
It's the reader's choice. It's 𝙮𝙤𝙪𝙧 choice. 🫵 But that doesn't make picking a winner any easier. Join us in recognizing and celebrating the incredible people, programs, and organizations making impact across the regon with your 𝘃𝗼𝘁𝗲 today and every day [between now and 11:59 p.m. EST Friday, December 13, 2024]. ➡ https://lnkd.in/er8piHHE There is no shortage of incredible finalists to choose from. Like... 🏆 Gene Mack and Gain Therapeutics 🏆 Raymond Cypess and ATCC 🏆 Atul Saran and IntegerBio 🏆 Robert Ross and Clasp Therapeutics 🏆 Michael Feld and BD 🏆 Yolanda L. Langhorne, EdD and the UMB CURE Scholars Program 🏆 Luis Alvarez and Theradaptive 🏆 Patrick Hanley, Ph.D. and Children's National Hospital 🏆 Chad Clark and Precision For Medicine 🏆 Howard Carolan and CoapTech 🏆 Jesse Christopher and Longeviti Neuro Solutions 🏆 Nicanor Aquino and Montgomery College 🏆 Bert Vogelstein and The Johns Hopkins University 🏆 Debra Hettleman and Building STEPS 🏆 Ned McCoy and Civica Rx 𝘼𝙣𝙙 𝙨𝙤 𝙢𝙖𝙣𝙮 𝙢𝙤𝙧𝙚... 👏 Stay tuned over the coming weeks as we celebrate our finalists and their incredible impact. ➕ Plus, a huge 𝙏𝙃𝘼𝙉𝙆 𝙔𝙊𝙐 to our partners who made this year's Awards possible: US Pharmacopeia (USP), Avantor, MilliporeSigma, Blackbird Laboratories, Integral Molecular, and Life Science Wealth. #leadership #innovation #community #workforce #lifesciences #maryland #virginia
Tune in to a thoughtful conversation from #SfN24 between our very own Senior Vice President of Research Joanne Taylor and Megan Thomas from Drug Discovery World. Listen here: https://lnkd.in/gGYkv9_n
Oral GT-02287 seen to safely enter brain in early #Parkinson's clinical trial GCase activity in dried blood spots increased approximately 53% in healthy volunteers. Phase 1b clinical trial expected to initiate by EOY 2024. https://lnkd.in/edscRnNH
Gain Therapeutics reposted this
I had the pleasure of speaking with Gene Mack, Interim CEO & CFO of Gain Therapeutics. Gene brings a unique perspective from his time on Wall Street, shedding light on how biotech financing has evolved. In our conversation, we dive deep into Gain Therapeutics' approach to neurodegenerative diseases, especially their work on Parkinson's. Gene shares his insights on the critical shift from simply managing symptoms to addressing the underlying biology of these diseases—an approach that holds promise for patients and the industry alike.
💡 Thrilled to bring you an inspiring conversation hosted by Rahul Chaturvedi with Gene Mack, Interim CEO & CFO of Gain Therapeutics, in our latest #Biotech2050 podcast episode! 🎧 Gene shares his extraordinary journey from a budding neurosurgeon to a biotech visionary, leading the charge on a groundbreaking approach to Parkinson's treatment. 🎙️ Dive in as he reveals: ✨ Insights from his unique career path—from clinical research to Wall Street, and finally, biotech leadership ✨ Gain Therapeutics’ pioneering work in disease-modifying treatments for Parkinson’s, aiming beyond symptom relief to address the root causes ✨ Real talk on navigating today’s challenging biotech landscape, from financing to clinical trials This episode is packed with insights for anyone passionate about the intersection of science, leadership, and impact in biotech. Listen, learn, and be inspired by a leader transforming the future of neuroscience! 🌍🔬 Link here: https://lnkd.in/gVwJzFbw #BiotechInnovation #Neuroscience #ParkinsonsResearch #Leadership #Biotech #CuttingEdgeScience #Biotechpodcast #NeurodegenerativeDisease #ParkinsonsBreakthrough #Biotech2050podcast